A detailed history of Oppenheimer & CO Inc transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Oppenheimer & CO Inc holds 19,289 shares of NBIX stock, worth $2.44 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
19,289
Previous 17,238 11.9%
Holding current value
$2.44 Million
Previous $2.37 Million 6.45%
% of portfolio
0.03%
Previous 0.04%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

BUY
$114.58 - $153.15 $235,003 - $314,110
2,051 Added 11.9%
19,289 $2.22 Million
Q2 2024

Aug 07, 2024

BUY
$130.86 - $143.19 $37,033 - $40,522
283 Added 1.67%
17,238 $2.37 Million
Q1 2024

May 06, 2024

SELL
$130.4 - $143.74 $27,905 - $30,760
-214 Reduced 1.25%
16,955 $2.34 Million
Q4 2023

Feb 13, 2024

BUY
$106.07 - $132.76 $26,411 - $33,057
249 Added 1.47%
17,169 $2.26 Million
Q3 2023

Nov 07, 2023

BUY
$94.02 - $117.1 $41,086 - $51,172
437 Added 2.65%
16,920 $1.9 Million
Q2 2023

Aug 02, 2023

BUY
$89.53 - $104.87 $2,238 - $2,621
25 Added 0.15%
16,483 $1.55 Million
Q1 2023

May 10, 2023

SELL
$94.11 - $123.02 $333,055 - $435,367
-3,539 Reduced 17.7%
16,458 $1.67 Million
Q4 2022

Feb 07, 2023

BUY
$106.72 - $127.06 $157,198 - $187,159
1,473 Added 7.95%
19,997 $2.39 Million
Q3 2022

Nov 14, 2022

BUY
$92.03 - $107.81 $575,831 - $674,567
6,257 Added 51.01%
18,524 $1.97 Million
Q2 2022

Aug 08, 2022

BUY
$75.79 - $100.07 $10,989 - $14,510
145 Added 1.2%
12,267 $1.2 Million
Q1 2022

May 12, 2022

SELL
$72.45 - $94.81 $11,881 - $15,548
-164 Reduced 1.33%
12,122 $1.14 Million
Q4 2021

Feb 02, 2022

BUY
$79.65 - $106.22 $511,591 - $682,251
6,423 Added 109.55%
12,286 $1.05 Million
Q3 2021

Nov 12, 2021

BUY
$86.18 - $99.03 $15,770 - $18,122
183 Added 3.22%
5,863 $562,000
Q2 2021

Aug 03, 2021

BUY
$89.43 - $102.27 $159,274 - $182,142
1,781 Added 45.68%
5,680 $553,000
Q1 2021

May 10, 2021

SELL
$87.57 - $119.4 $1,401 - $1,910
-16 Reduced 0.41%
3,899 $379,000
Q4 2020

Feb 11, 2021

BUY
$86.91 - $108.33 $11,124 - $13,866
128 Added 3.38%
3,915 $375,000
Q3 2020

Nov 13, 2020

BUY
$96.16 - $135.15 $73,850 - $103,795
768 Added 25.44%
3,787 $364,000
Q2 2020

Aug 11, 2020

SELL
$85.09 - $130.36 $24,165 - $37,022
-284 Reduced 8.6%
3,019 $369,000
Q1 2020

May 08, 2020

SELL
$75.11 - $113.76 $245,159 - $371,312
-3,264 Reduced 49.7%
3,303 $286,000
Q4 2019

Feb 07, 2020

BUY
$86.8 - $118.57 $52,340 - $71,497
603 Added 10.11%
6,567 $706,000
Q3 2019

Oct 31, 2019

BUY
$83.82 - $101.5 $274,091 - $331,905
3,270 Added 121.38%
5,964 $537,000
Q2 2019

Aug 09, 2019

SELL
$72.24 - $91.27 $303,046 - $382,877
-4,195 Reduced 60.89%
2,694 $227,000
Q1 2019

Apr 24, 2019

BUY
$69.31 - $91.53 $122,886 - $162,282
1,773 Added 34.66%
6,889 $607,000
Q4 2018

Jan 29, 2019

SELL
$68.32 - $124.36 $90,797 - $165,274
-1,329 Reduced 20.62%
5,116 $365,000
Q3 2018

Oct 26, 2018

BUY
$98.88 - $125.85 $303,363 - $386,107
3,068 Added 90.85%
6,445 $792,000
Q2 2018

Aug 10, 2018

SELL
$75.3 - $105.99 $11,972 - $16,852
-159 Reduced 4.5%
3,377 $332,000
Q1 2018

May 01, 2018

BUY
$75.88 - $92.43 $268,311 - $326,832
3,536 New
3,536 $293,000

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12.1B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Oppenheimer & CO Inc Portfolio

Follow Oppenheimer & CO Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Oppenheimer & CO Inc, based on Form 13F filings with the SEC.

News

Stay updated on Oppenheimer & CO Inc with notifications on news.